In this setting also, the use of CaMKII inhibitors can help to understand the molecular elements of the CaMKII-ERK interaction and their functional significance, with the perspective of a novel therapeutic approach to limit pathological cardiac hypertrophy. This evidence concerns the gene CAMK2G and cardiac hypertrophy.